Literature DB >> 23455624

[Hypereosinophilic syndrome].

F Moosig1, G Richardt, C Merten, W L Gross.   

Abstract

Hypereosinophilic syndrome is a heterogeneous group of diseases characterized by blood hypereosinophilia and eosinophil-related organ damage. A comprehensive diagnostic work-up is necessary to identify underlying conditions and to detect organ involvement, which are important for prognosis. Involvement of the heart is related with a poorer outcome. Some underlying conditions can be treated with targeted therapies, e.g., tyrosine kinase inhibitors. However, glucocorticoids in combination with steroid-sparing drugs are generally used for treatment. Furthermore, the growing understanding of the molecular pathogenesis will lead to new therapies, e.g., the use of anti-cytokine antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455624     DOI: 10.1007/s00108-012-3189-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  19 in total

1.  Getting rid of MPO-ANCA: a matter of disease subtype.

Authors:  Jan P Bremer; Elena Csernok; Julia Holle; Wolfgang L Gross; Frank Moosig
Journal:  Rheumatology (Oxford)       Date:  2013-01-23       Impact factor: 7.580

2.  Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Authors:  Florence Roufosse; Aurore de Lavareille; Liliane Schandené; Elie Cogan; Ann Georgelas; Lori Wagner; Liqiang Xi; Mark Raffeld; Michel Goldman; Gerald J Gleich; Amy Klion
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

3.  A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.

Authors:  R T Schooley; M A Flaum; H R Gralnick; A S Fauci
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

Review 4.  Churg-Strauss syndrome: update on pathophysiology and treatment.

Authors:  Augusto Vaglio; Frank Moosig; Jochen Zwerina
Journal:  Curr Opin Rheumatol       Date:  2012-01       Impact factor: 5.006

5.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  Treatment of hypereosinophilic syndrome with imatinib mesilate.

Authors:  Gerald J Gleich; Kristin M Leiferman; Animesh Pardanani; Ayalew Tefferi; Joseph H Butterfield
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

Authors:  Jorge Cortes; Patricia Ault; Charles Koller; Deborah Thomas; Alessandra Ferrajoli; William Wierda; Mary B Rios; Laurie Letvak; Elizabeth S Kaled; Hagop Kantarjian
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

8.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Authors:  Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Journal:  Br J Haematol       Date:  2008-10-17       Impact factor: 6.998

9.  A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.

Authors:  Frank Moosig; Jan Phillip Bremer; Bernhard Hellmich; Julia Ulrike Holle; Konstanze Holl-Ulrich; Martin Laudien; Christine Matthis; Claudia Metzler; Bernhard Nölle; Gert Richardt; Wolfgang L Gross
Journal:  Ann Rheum Dis       Date:  2012-08-11       Impact factor: 19.103

10.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.